The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum-Reference-Cited by-同舟云学术

The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum

Published:2023-05 Issue:5 Volume:29 Page:576-581
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Tice Jeffrey A¹,Walton Surrey M²,Sarker Jyotirmoy²,Moradi Ashton³,Chu Janet N¹,Herce-Hagiwara Belen³,Fahim Shahariar Mohammed³,Agboola Foluso³,Rind David³,Pearson Steven D³

Affiliation:

1. Division of General Internal Medicine, University of California San Francisco.

2. Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago.

3. Institute for Clinical and Economic Review, Boston, MA.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference7 articles.

1. Hemophilia A

2. Aspects of prophylactic treatment of hemophilia

3. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

4. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B;Journal of Managed Care & Specialty Pharmacy;2024-08

2. Separation of full, empty, and partial adeno-associated virus capsids via anion-exchange chromatography with continuous recycling and accumulation;Journal of Chromatography B;2024-07

3. Perspectives and perception of haemophilia gene therapy by French patients;Haemophilia;2023-12-06